Precision's Jason Shafrin identifies three key trends to consider when assessing the value of new innovations for 2021.
The COVID-19 pandemic has put the inequality in health outcomes in the United States center stage. What can the healthcare industry do to begin to address disparities in health outcomes?
Creating Incentives To Narrow The Gap In Health Outcomes: Expanding Value Assessment To Incorporate Health Inequality
Adding to the ongoing national dialogue on racial inequality, PRECISIONheor’s Jason Shafin and Meena Venkatachalam join the conversation in their Health Affairs blog post: “Creating Incentives To Narrow The Gap In Health Outcomes: Expanding Value Assessment To Incorporate Health Inequality”.
ISPOR's “value flower” versus the traditional QALYs approach: Precision's Jason Shafrin, Kathy Lang and Ross Maclean discuss why the “value flower” model can more accurately value treatments - in cases like COVID-19 - which have a transformational impact on the lives of not only of patients, but also caregivers, employers, and broader society.
Real-World Data Will Continue to Provide Real Value to the Drug Development and Commercialization Process
Precision's Sajjad Raza and Kathy Lang identify emerging trends that suggest the use of real-world data will continue to grow and become pivotal, and the inherent challenges that must be addressed.
As employers consider including COVID-19 testing as part of their reopening plans, Precision experts Jacquelyn Chou, Caroline Huber and Jennifer Millard discuss the two key issues that must be resolved before antibody testing can be truly useful for an employer.
Precision's Jason Shafrin discusses the four major challenges to ICER's approach to value-based price recommendations, and how an open source approach could overcome these challenges.
CAR-T therapy breaks a pattern of stagnant efficacy growth in pharmaceutical innovation. A new CAR-T therapy study demonstrates significantly greater incremental effectiveness and similar cost–effectiveness to previous anticancer treatments.
By limiting the benefits included in its model and inappropriately valuing these health benefits, ICER risks mispricing innovative health therapies and disincentivizing investments in research and development.
In this article, we explore critical factors in the development of gene therapies, including trial management, accelerated approval pathways, and companion diagnostic development and its coordination with therapeutic development.